[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2013-2023

July 2013 | 174 pages | ID: P388D0FE3D1EN

US$ 2,635.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Generics companies - assess products, developments, and revenue prospects

What does the future hold for makers of generic drugs? Visiongain's updated report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 50 leading generics producers and marketers. There you find information on established and rising companies. Discover their sales potentials.

Forecasts and other data to help you stay ahead

In our new study you find analytical profiles of top companies worldwide. There you analyse historical data, market shares, revenue forecasts, and growth rates. Discover qualitative analysis too. You also gain 63 charts and 96 tables.

Our work lets you assess the most lucrative parts of the world industry for generic drugs. See now how you can benefit your research, analyses, and decisions there, also saving time.

The following sections highlight what you find in our new investigation.

Assessments of top companies - activities, results, competition, and potential sales

Our report analyses 50 manufacturers of generic medicines. In general a company profile gives you the following information:
  • Discussion of a company's activities, outlook, and recent financial results
  • Assessment of its developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures
  • Forecasting of generic drug revenues to 2023 (for 20 of the companies).
Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Now see companies you investigate there, grouped by type and geographical region.

Big pharma - generics production by the pharma industry's largest companies

First, our study gives you discussions, financial analyses, and commercial outlooks for five generic drug producers among the world's leading pharmaceutical companies:
  • Teva Pharmaceutical Industries
  • Novartis (Sandoz)
  • Abbott Laboratories
  • Pfizer
  • Sanofi.
You see possibilities there for raising business performance. Discover what the future holds for those companies, then, including revenue predictions to 2023.

North America - outlooks for leading generic drug manufacturers

Next, our report analyses 12 North American generics specialists, including these:
  • Mylan
  • Actavis
  • Hospira
  • Par Pharmaceutical
  • Mallinckrodt
  • Apotex
  • Valeant.
There you find where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. See where best potentials exist.

Europe - prospects for leading generics players

You also discover outlooks for 11 European generics specialists, including these:
  • Fresenius Kabi
  • Pharmstandard
  • Stada Arzneimittel
  • Gedeon Richter
  • Krka.
Our report shows you how companies can seize opportunities and expand their businesses.

India - analysis of leading generic drug firms

Our new work also assesses 10 Indian generic drug producers, including these:
  • Ranbaxy Laboratories
  • Cipla
  • Dr. Reddy's Laboratories
  • Lupin
  • Aurobindo
  • Wockhardt
  • Sun Pharmaceutical Industries.
How much sales growth and geographical expansion can Indian pharma achieve? You find revenue data, trends, and opportunities there, seeing what the present and future hold.

Producers from the rest of the world - assess progress and prospects

You also discover outlooks for 12 generic drug makers based in other regions, including these companies:
  • Aspen Pharmacare
  • Laboratorios Roemmers
  • Nichi-Iko
  • Sawai Pharmaceuticals
  • Taro Pharmaceutical Industries
  • Adcock Ingram
  • Eurofarma.
Developing markets such as Japan, Brazil and China will prove important for generic drug sales from 2013 to 2023, our analyses show.

Issues affecting generic drug manufacturing and selling

In addition, our report discusses issues and events affecting that industry and market from 2013, including these:
  • Specialty generics - difficult-to-produce medicines with high profit margins
  • Super-generics - shift towards innovation, with expanding R&D budgets
  • Mergers and acquisitions influencing that part of healthcare
  • Big pharma firms targeting generics - diversification of portfolios
  • Expansion internationally - targeting emerging national markets
  • Intellectual property (IP) - regulation and opportunity
  • Biosimilars - opportunities for generic and originator companies.
There you explore the generic drug industry's strengths, weaknesses, opportunities, and threats. In particular, the merger of Actavis and Watson forms a notable event. Discover now what the future holds.

Ways Pharma Leader Series: Top 50 Generic Drug Manufacturers 2013-2023 helps you

In summary, then, our new research and analysis give you the following knowledge:
  • Profiles of 50 leading companies - assess product ranges, strategies, and sales results, also gaining revenue forecasts to 2023 for 20 organisations
  • Competition and opportunities - see what affects the generics market, learning what shapes its future, esp. prospects for sustaining and developing business
  • Analysis of what stimulates and restrains the generic medicines industry - discover challenges and strengths, helping you compete and gain advantages
  • Issues affecting established competitors and firms entering the generics sector - explore needs, practices, and outlooks for future success.
Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Predictions for generic drug production and sales - gain by ordering now

Our new analysis shows you data, trends, opportunities, and outlooks for producers and sellers of generic drugs. Avoid missing out - please order our report now.

1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods


2.1 Total Value of the Top 50 Generics Companies
2.2 Regional Distribution of the Top 50 Companies
2.3 Coverage in this Report
  2.3.1 Issues Involved in Assessing the Top 50 Companies
  2.3.2 Obtaining Data for Private Companies
  2.3.3 Variable Financial Years
  2.3.4 Identifying Revenues Specifically from Generics
  2.3.5 Defining Generics 1: Do Biosimilars Count?
  2.3.6 Defining Generics 2: 'Super-Generics' and APIs
  2.3.7 Defining Generics 3: Rx and OTC


3.1 Companies Covered in this Chapter
3.2 Why are Big Pharma Targeting Generics?
  3.2.1 Is Generics Still a Dirty Word for Big Pharma?
  3.2.2 Diversification or Divorce? Big Pharma Growth Strategies
3.3 Teva Pharmaceutical Industries: Still the Generics Industry Leader
  3.3.1 Teva's Shift Towards Innovation
  3.3.2 High-Value Generics to Drive Teva's Generics Growth
  3.3.3 Handok Joins Teva's Long Acquisitions List
  3.3.4 Teva's Global Presence
  3.3.5 Growth Forecast for Teva Generics 2013-2023
3.4 Novartis: Leader in Biosimilars and Complex Generics
  3.4.1 Enoxaparin Exclusivity Loss Hits Sandoz Profits in 2012
  3.4.2 Emphasis on Difficult-to-Manufacture Products
  3.4.3 Europe the Main Market for Sandoz Despite German Decline
  3.4.4 Growth Forecast for Novartis Generics 2013-2023
3.5 Abbott Laboratories: Ahead in India Through Generic Strength
  3.5.1 Established Products Stays with Abbott Laboratories After the 2012 Abbvie Spin-Off
  3.5.2 Abbott's Businesses
  3.5.3 Will Established Products' Performance Improve in 2013?
  3.5.4 Abbott Targeting Emerging Markets for 50% for Future Revenues
  3.5.5 Acquiring Market Share in India and the CEE Nations in 2013?
  3.5.6 Growth Forecast for Abbott Generics 2013-2023
3.6 Pfizer: Vast Established Products Portfolio
  3.6.1 More Restructuring to Follow at Pfizer?
  3.6.2 Maximising Mature Product Value
  3.6.3 Estimating Value for Pfizer's Generics
  3.6.4 BRIC Nations, Turkey, Mexico and Japan Among Target Markets for Pfizer Generics
  3.6.5 Growth Forecast for Pfizer Generics 2013-2023
3.7 Sanofi: Focused Generics Strategy for Emerging Markets
  3.7.1 Generics at the Forefront of Sanofi's Leadership in the Emerging Markets
  3.7.2 Genfar Acquisition Boosts Sanofi's Latin America Strategy
  3.7.3 Zentiva Brand Still Strong in CEE Markets
  3.7.4 Diversification to Offset Patent Cliff Threat to Revenues
  3.7.5 Growth Forecast for Sanofi Generics 2013-2023


4.1 Companies Covered in this Chapter
4.2 Domestic Companies Still Prominent in the US, the Largest Market
4.3 Mylan: Second-Largest Player in the US Market
  4.3.1 EPIPEN Drives Mylan's Diversification Into Original Products
  4.3.2 Generics Remain the Core Strength for Mylan
  4.3.3 Generics Portfolio Over 1,100 Products Strong
  4.3.4 First Class II Transdermal Approval Consolidates Mylan's Top Two Status in the US Market
  4.3.5 Tender System Hurts Mylan's German Market Share, But Company Retains Australasian Dominance
  4.3.6 Growth Forecast for Mylan Generics 2013-2023
4.4 Actavis: Merger Creates New Force in Generics Market
  4.4.1 Over 40 Branded Product Lines
  4.4.2 Merged Generics Business to Have ~10% US Market Share
  4.4.3 Warner Chilcott Acquisition Silences Rumours of Actavis Takeover
  4.4.4 Actavis/Watson Merger Builds on Strong M&A History for Both Companies
  4.4.5 Actavis' Biosimilar Ambitions
  4.4.6 Growth Forecast for Actavis Generics, 2013-2023
4.5 Hospira: Injectables Expert Still Among Top 10 Generics Players
  4.5.1 Leader in Acute Care and Oncology Generics
  4.5.2 Celltrion Collaboration in Biosimilars Sector
  4.5.3 Generics Still the Core Business for Hospira
  4.5.4 Integrated Infusion Therapies and other Hospira Businesses
  4.5.5 Orchid Acquisition Signalling an Indian Strategy for Hospira?
  4.5.6 Growth Forecast for Hospira Generics, 2013-2023
4.6 Par Pharmaceutical: Largest Private Player Among the North American Companies
  4.6.1 TPG Paid $50 Per Share for Par in 2012
  4.6.2 Over 60 Generic Prescription Drug Families
  4.6.3 Anchen Acquisition Demonstrates Par's Interest in Niche Products
  4.6.4 Megace and Other Par Controversies
4.7 Mallinckrodt: Generic CNS Specialist to Spin Off From Covidien Healthcare
  4.7.1 Medical Devices the Major Interest for Covidien
  4.7.2 Generic Concerta a Major Addition to the Company's Portfolio
  4.7.3 CNS Therapeutics Acquisition Will Strengthen Mallinckrodt's Position
4.8 Apotex: Leading Canadian Generic Firm
  4.8.1 Expansion To Europe and Beyond
  4.8.2 R&D-Driven Business Diversification
  4.8.3 Generics Still Major Growth Driver, Despite Clashes with FDA
4.9 Valeant: Rapidly-Growing Quebec Firm is One to Watch
  4.9.1 A Major Challenger in the Emerging Markets
  4.9.2 Highly Ambitious Acquisitions Policy, Despite Actavis Miss
  4.9.3 Branded Generics Key to Valeant's Emerging Market Ambitions
4.10 Endo Health Solutions: Sixth in the US Market by Prescription Volume
  4.10.1 Pain Expertise in Branded and Generic Drugs
  4.10.2 Strong Prospects for the Qualitest Business
4.11 Perrigo Company: OTC and Infant Formula Giant
  4.11.1 Perrigo Company: OTC and Infant Formula Giant
  4.11.2 Paddock Acquisition Drives 80% Generics Segment Growth
4.12 Pharmascience: Another Major Canadian Player
  4.12.1 Over 200 Generic Product Families
  4.12.2 Korean Venture Driving Diversification for Pharmascience
4.13 Impax Laboratories: Generics Presence in US and Taiwan
  4.13.1 Fenofibrate Sales Driving Generics Segment
  4.13.2 Rytary Heading Impax's Push Into Proprietary Products
4.14 Hi-Tech Pharmacal: Delaware-Based Pharma Still a Significant Player
  4.14.1 Generics Represented Over 80% of Revenues in 2012
  4.14.2 Fluticasone a Major Driver


5.1 Companies Covered in this Chapter
5.2 CEE Markets Home to Many Big Generics Contenders
5.3 Fresenius Kabi: Leading Generic IV Player
  5.3.1 Broad IV Drugs Portfolio
  5.3.2 Infusion Therapies and Medical Devices Also Strong Areas
  5.3.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
  5.3.4 Expansion Into Vietnam and Chile in 2012
  5.3.5 Growth Forecast for Fresenius Kabi Generics, 2013-2023
5.4 Pharmstandard: Russia's Leading Domestic Generics Company
  5.4.1 TPP Sales a Key Growth Driver for Pharmstandard
  5.4.2 Organic Production Capacity
  5.4.3 2012 Acquisition of Lekko and Others Strengthens Pharmstandard's Manufacturing Base
  5.4.4 Growth Forecast for Pharmstandard Generics, 2013-2023
5.5 Stada Arzneimittel: Major Presence in Germany and Central Europe
  5.5.1 Still Predominantly Generics-Focused in 2012
  5.5.2 Over 700 Product Launches in 2012 Alone
  5.5.3 Positive Currency Effects From Pound and Rouble Boost European Performance
  5.5.4 Targeting the Biosimilars Sector
  5.5.5 Growth Forecast for Stada Arzneimittel, 2013-2023
5.6 Gedeon Richter: Hungarian Leader Looking Further Afield
  5.6.1 Esmya Represents First Original Product Launch for Richter
  5.6.2 Female Health and Fertility Key Strength for the Company
  5.6.3 Specialisation Strategy for Future Growth
  5.6.4 A Pan-European Pharmaceutical Presence for the Future?
  5.6.5 Growth Forecast for Gedeon Richter Generics 2013-2023
5.7 Krka: Slovenian Generics Giant Active in 70+ Countries
  5.7.1 Prescription Generics Major Company Focus
  5.7.2 Atorvastatin a $75m+ Bonus for the Company in 2012
  5.7.3 Leading Statins Supplier in CEE
  5.7.4 Russia Remains the Largest National Market for Krka
  5.7.5 Growth Forecast for Krka Generics 2013-2023
5.8 Abdi Ibrahim: Turkey's Leading Pharmaceutical Company
  5.8.1 Over 250 Different Products in 11 Therapeutic Areas
  5.8.2 Otsuka Joint Venture the Latest Abdi Ibrahim Collaboration
  5.8.3 Increasing International Scope
5.9 Polpharma: Poland's Generics Powerhouse
  5.9.1 Substantial Portfolio Enlarged by Acquisitions
  5.9.2 Regional Presence in Poland, Russia and Kazakhstan
  5.9.3 Polfa Warszawa Acquisition Increases Dominance in Polish Market
5.10 Egis Pharmaceuticals: Important Player in Hungary and CEE
  5.10.1 Over 500 Products in Portfolio for 2012
  5.10.2 Cardiovascular Drugs the Key Portfolio Strength
  5.10.3 Russia and CIS the Biggest Markets
5.11 Orion Pharma: Diversified Finnish Company Retains Generics Interests
  5.11.1 Over 14% Growth for Generics Revenues in 2012
  5.11.2 Entacapone Lifecycle Management Aids Generics Segment
5.12 EastPharma: Bermuda-Based Holding Company With Growing Significance in Turkish Market
  5.12.1 Substantial Manufacturing Capacity Within Turkey
  5.12.2 Roche Licensing Deal Strengthens Deva/Saba Generics Portfolio
5.13 Veropharm: Russian Oncology Market Leader
  5.13.1 Manufacturing Capacity of ~600m Tables Annually
  5.13.2 Fourth-Ranked in Russian Market in 2012


6.1 Companies Covered in this Chapter
6.2 India: Generics Supplier to the World
6.3 Ranbaxy Laboratories: Indian Leader With Sales in 150+ Markets
  6.3.1 Over $1bn in US Revenues, But Will Controversy Prove a Permanent Setback for Ranbaxy in America?
  6.3.2 Fallout from the Case
  6.3.3 Ranbaxy Extending Global Reach With Assistance of Daiichi Sankyo
  6.3.4 Dermatology Therapeutic Area Targeted for Growth
  6.3.5 Growth Forecast for Ranbaxy Generics, 2013-2023
6.4 Cipla: Mumbai-Based Generics Giant
  6.4.1 Generic Copaxone Added to Extensive Portfolio
  6.4.2 Leadership in Antiretroviral Drugs
  6.4.3 Chronic Diseases a Significant Target for Cipla
  6.4.4 Maintaining a Strong Tradition of Patent Challenges
  6.4.5 Growth Forecast for Cipla Generics, 2013-2023
6.5 Dr. Reddy's Laboratories: At the Forefront of Indian Generics Boom
  6.5.1 Company Revenues Exceeded $2bn in 2012
  6.5.2 North America and Russia Largest Export Markets
  6.5.3 GlaxoSmithKline Alliance Supplements Strong M&A Strategy
  6.5.4 Early Leadership in Biosimilar Antibodies
  6.5.5 Growth Forecast for Dr. Reddy's Laboratories' Generics, 2013-2023
6.6 Lupin: Most Successful Indian Generics Firm in the US Market
  6.6.1 Portfolio Growth Continued Strongly in 2012
  6.6.2 Cephalosporins and Anti-TB Drugs a Portfolio Highlight
  6.6.3 Strong R&D Investment in New Delivery Systems and Original Products
  6.6.4 Growth Forecast for Lupin Generics, 2013-2023
6.7 Aurobindo: Largest FDA API Supplier, Now Moving Into Original Drugs
  6.7.1 High-Margin Specialty Generics The Target
  6.7.2 145 ANDAs FDA-Approved By 2012
  6.7.3 CRAMS Opportunities
6.8 Wockhardt: Increasing Presence in US and European Generics Markets
  6.8.1 78% Growth in the US Market in 2012
  6.8.2 Biosimilars, Novel Delivery Systems and Original Drugs to Drive Future Growth
6.9 Sun Pharma: Exporting to Four Continents
  6.9.1 Major Presence in Generic Export Markets
  6.9.2 Meda Acquisition to Enlarge Sun's Operations?
6.10 Zydus Cadila: Leader in Indian Cardiovascular Market
  6.10.1 Biochem Acquisition Boosts Zydus in 2012
  6.10.2 Increasing Presence in the US Market
  6.10.3 A Future Biosimilars Force?
6.11 Strides Arcolab: Former Leader in Sterile Injectables
  6.11.1 Mylan Buys Injectables Business for $1.6bn in 2013
  6.11.2 Singapore, Australasia and West Africa Growth Areas
6.12 Glenmark: Specialty Company Still Leveraging Generics for Growth
  6.12.1 Generics Remain Part of Global Growth Strategy for Glenmark
  6.12.2 US Exports Boom, and API Export Business Enters Japan


7.1 Companies Covered in this Chapter
7.2 Japanese and Brazilian Generics Environments Particularly Significant to Global Market
7.3 Aspen Pharmacare: South African Giant Continues to Expand
  7.3.1 Ten-Year CAGR to 2012 Exceeds 25%
  7.3.2 Philippines Added to Areas of Activity
  7.3.3 Continuing 30%+ Dominance in South African Generics Market
  7.3.4 Asia-Pacific the Main Growth Area in 2012
  7.3.5 Latin America Another Major Growth Opportunity
  7.3.6 Growth Forecast for Aspen Generics, 2013-2023
7.4 Roemmers: Argentina's Leading Player
  7.4.1 Expansion Into New Markets
  7.4.2 Still Dominant in Domestic Market Despite Challenge From BagГі and Gador
  7.4.3 Growth Forecast for Roemmers Generics, 2013-2023
7.5 Nichi-Iko: First Japanese Firm to Make the Top
  7.5.1 Nearly 600 Generic Products in Portfolio
  7.5.2 Sanofi Venture Complements M&A Strategy
  7.5.3 Growth Forecast for Nichi-Iko Generics, 2013-2023
7.6 Sawai Pharmaceuticals: Osaka-Based Generics Leader
  7.6.1 Annual Manufacturing Capacity of 10bn Tablets
  7.6.2 Cardiovascular Drugs the Most Significant Therapeutic Area
  7.6.3 M&A Boosts R&D
7.7 Hikma: Leader in the MENA Markets
  7.7.1 Oral and Injectable Generics
  7.7.2 An Obstacle to Hikma's US Generics Growth?
  7.7.3 Strong M&A History
7.8 Taro Pharmaceutical Industries: Rapidly-Growing Israeli Manufacturer
  7.8.1 Sun Abandons Takeover Plans in 2013
  7.8.2 FDA Corticosteroid Spray Approval Boosts Portfolio in 2013
7.9 Adcock Ingram: South Africa's Other Major Player a Noted M&A Target
  7.9.1 Expansion Into Ghana and Kenya
  7.9.2 A Likely Acquisition in 2013 - But For Whom?
7.10 Towa Pharmaceutical: Another Big Japanese Player
  7.10.1 Portfolio Nears 600 Generic Products
  7.10.2 Broad and Expanding Production Capacity
7.11 EMS: Leading the Brazilian Generics Market
  7.11.1 First Brazilian Company to Export Generics to Europe
  7.11.2 Most Advanced Latin American R&D Base
7.12 Eurofarma: Rapidly-Growing Generics Power in Brazil
  7.12.1 Eight Diversified Business Divisions
  7.12.2 M&A Extending Latin American Reach of Eurofarma
7.13 NeoQuimica: Hypermarcas-Owned Firm Now Brazil's Third-Largest
  7.13.1 A Growing Generics Presence Since 2000
  7.13.2 Substantial Portfolio Offering Significant Growth Prospects
7.14 Nippon Chemiphar: Generics Drive Growth for Tokyo-Based Pharma Company
  7.14.1 Interests in Diagnostics and Original Products
  7.14.2 Generics, Cosmetics and Health Food Key Business Components


8.1 Watson and Actavis Merger: A First Major Consolidation for the Generics Industry
8.2 Teva in 2012: A Top Ten Big Pharma Company, and a Majority Generics Company for the Last Time
8.3 Big Pharma Business Models Evolve: Abbott Breaks Up, Novartis Now Biggest Player
8.4 Biosimilars Will Have a Transformative Effect on Generic and Originator Companies Alike
8.5 Complex Generics With High Entry Barriers Continue to Grow in Importance
8.6 First Japanese Company Enters the Top 20 in 2012
8.7 India's New Aggression over IP
8.8 Likely Future Trends: Summary


Table 2.1 Top 50 Generic Pharmaceutical Manufacturers: Revenues ($m) and Ranking, 2012
Table 3.1 Top Big Pharma Generic Manufacturers, Revenues ($m), Rank, 2012
Table 3.2 Teva Pharmaceutical Industries: Overview, 2012
Table 3.3 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.4 Teva Pharmaceutical Industries: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.5 Novartis: Overview, 2012
Table 3.6 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.7 Novartis: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.8 Abbott Laboratories: Overview, 2012
Table 3.9 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.10 Abbott: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.11 Pfizer: Overview, 2012
Table 3.12 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.13 Pfizer: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.14 Sanofi: Overview, 2012
Table 3.15 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.16 Sanofi: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.1 Top North American Generic Manufacturers, Revenues ($m), Rank, 2012
Table 4.2 Mylan: Overview, 2012
Table 4.3 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.4 Mylan: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.5 Actavis: Overview, 2012
Table 4.6 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.7 Actavis: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.8 Hospira: Overview, 2012
Table 4.9 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.10 Hospira: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.11 Par Pharmaceutical: Overview, 2012
Table 4.12 Covidien: Overview, 2012
Table 4.13 Apotex: Overview, 2012
Table 4.14 Valeant: Overview, 2012
Table 4.15 Endo Health Solutions: Overview, 2012
Table 4.16 Perrigo Company: Overview, 2012
Table 4.17 Pharmascience: Overview, 2012
Table 4.18 Impax Laboratories: Overview, 2012
Table 4.19 Hi-Tech Pharmacal: Overview, 2012
Table 5.1 Top European Generic Manufacturers, Revenues ($m), Rank, 2012
Table 5.2 Fresenius Kabi: Overview, 2012
Table 5.3 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.4 Fresenius Kabi: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.5 Pharmstandard: Overview, 2012
Table 5.6 Pharmstandard: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.7 Pharmstandard: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.8 Stada Arzneimittel: Overview, 2012
Table 5.9 Stada Arzneimittel: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.10 Stada Arzneimittel: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.11 Gedeon Richter: Overview, 2012
Table 5.12 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.13 Gedeon Richter: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.14 Krka: Overview, 2012
Table 5.15 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.16 Krka: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.17 Abdi Ibrahim: Overview, 2012
Table 5.18 Polpharma: Overview, 2012
Table 5.19 Egis Pharmaceuticals: Overview, 2012
Table 5.20 Orion: Overview, 2012
Table 5.21 EastPharma: Overview, 2012
Table 5.22 Veropharm: Overview, 2012
Table 6.1 Top Indian Generic Manufacturers, Revenues ($m), Rank, 2012
Table 6.2 Ranbaxy: Overview, 2012
Table 6.3 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.4 Ranbaxy: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.5 Cipla: Overview, 2012
Table 6.6 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.7 Cipla: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.8 Dr. Reddy's Laboratories: Overview, 2012
Table 6.9 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.10 Dr. Reddy's: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.11 Lupin: Overview, 2012
Table 6.12 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.13 Lupin: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.14 Aurobindo: Overview, 2012
Table 6.15 Wockhardt: Overview, 2012
Table 6.16 Sun Pharma: Overview, 2012
Table 6.17 Zydus Cadila: Overview, 2012
Table 6.18 Strides Arcolabs: Overview, 2012
Table 6.19 Glenmark: Overview, 2012
Table 7.1 Top Rest of the World Generic Manufacturers, Revenues ($m), Rank, 2012
Table 7.2 Aspen: Overview, 2012
Table 7.3 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 7.4 Aspen: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 7.5 Laboratorios Roemmers: Overview, 2012
Table 7.6 Roemmers: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 7.7 Roemmers: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 7.8 Nichi-Iko: Overview, 2012
Table 7.9 Nichi-Iko: Generic Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 7.10 Nichi Iko: Generic Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 7.11 Sawai: Overview, 2012
Table 7.12 Hikma: Overview, 2012
Table 7.13 Taro Pharmaceutical Industries: Overview, 2012
Table 7.14 Adcock Ingram: Overview, 2012
Table 7.15 Towa Pharmaceutical: Overview, 2012
Table 7.16 EMS: Overview, 2012
Table 7.17 Eurofarma: Overview, 2012
Table 7.18 NeoQuimica: Overview, 2012
Table 7.19 Nippon Chemiphar: Overview, 2012

Orchid Acquisition Signalling an Indian Strategy for Hospira?

In August 2012, Hospira acquired Orchid Chemicals & Pharmaceuticals’ penem and penicillin API business for just over $202m in cash. Orchid is an Indian company, and Hospira’s involvement with Orchid since 2010 is an indication the company will be expanding its operations in India in the near future. Hospira also acquired Javelin Pharmaceuticals in 2010, with the intent of using synergies between its leading Precedex product and Javelin’s post-operative pain management candidate drug Dyloject. Hospira also entered into collaborative agreements with DURECT Corporation and Kiadis Pharma. Hospira has also established a licensing deal for a ChemGenex oncology product candidate, and has acquired facilities and product rights in the biosimilars field from PLIVA Hrvatska, Human Genome Sciences and Celltrion. It has a joint venture (Zydus Hospira Oncology) with Cadila Healthcare.

Growth Forecast for Hospira Generics, 2013-2023

Visiongain believes Hospira’s generics business will achieve a 2012-2017 CAGR of 3% and reach sales of $2550m in that year. The relatively slow growth will result from increasing competition in the injectables segment, which has been targeted by multiple companies seeking opportunities in speciality generic pharma sectors. However, opportunities in new markets including India will see Hospira’s generics business (though the company’s other businesses may perform more strongly), reaching revenues of $3437m by the end of the forecast period, with a five-year CAGR of 5%.

More Publications